Genome Biologics

⏰ SAVE A DATE ⏰ Our CEO will attend the BIO 2022, which will take place in San Diego, USA from 13th – 16th June 2022. 👉 Don't hesitate to visit us at BOOTH #10 in European Pavilion to get your BEST SOLUTIONS 👈 More information: lnkd.in/gz8D733i #EUeic @EU_EISMEA

Thank you Hessen Trade & Invest for arranging a great meeting. We are looking for more to come.

Herzlichen Glückwunsch! Innovative hessische Unternehmen erhalten rund 19 Mio. € EU-Fördergelder #CO2BioClean @genomebiologics @magnotherm Solutions @EUeic @HTAI_Hessen #eencanhelp @EEN_Deutschland #EEN_Hessen htai.de/Pressemitteilu… © Erdmann & Erdmann Medien

Genome Biologics is proud to be selected as one of 20 pioneering companies to participate at "BIO International Convention 2022" in San Diego, USA from 13-16.06.2022. Meet us at BOOTH #10 in European Pavilion lnkd.in/gz8D733i

Genome Biologics is humbled to be the winner of the GHP Biotechnology Awards 2022 as "the Best Cardiovascular Disease Drug Development Provider". For more information: ghp-news.com/winners/genome…

February is American Heart Month, which promotes the attention to maintain heart health for all. Genome Biologics devotes to reduce the effects on heart diseases. Let join us to do 4 steps for a heathier heart. #cardiovascular

🎉 🏆🏆🏆 🎉 We are honored to be the WINNER of "European Awards in Medicine 21st Century". The Prizes were created to promote the excellence and knowledge through teaching, research and proactive networking. More information: lnkd.in/esF2gbMQ #drugdevelopment

🎉 👏 PUBLICATION NEWS 🎉 Our paper “Mitochondrial–cell cycle cross-talk drives endoreplication in heart disease” is featured in the Research Highlights section in the Nature Reviews Cardiology. lnkd.in/ez9f-FbG lnkd.in/eWG7cwf8

🔔🎄🎁 MERRY CHRISTMAS AND HAPPY NEW YEAR 🎊 🎉 May all that is beautiful, meaningful and brings you joy be yours this holiday season and throughout the coming year! #festivales #happyholidays #newbeginnings2022

🎉 BREAKING NEWS 🚀 Genome Biologics is honoured to be selected by the European Innovation Council (EIC) to receive up to €9.8M in equity funding to accelerate the development of our company and clinical programs for cardiovascular disease. lnkd.in/dmGQQTRc

OUR NEW PAPER IS PUBLISHED... This addresses the possibility of genetically altering Göttingen Minipigs using a new rapid one-step genetic technology (GENISYST®) in order to replicate genetic alterations responsible for human disease. More information at: lnkd.in/dsADw-a

The EU Commission has accepted a Recommendation on a European Electronic Health Record exchange format. This will help the citizens to securely access and exchange their health data within in EU. For more information: ec.europa.eu/digital-single… #electronichealthrecords #Innovations

The end of 2020 drew to a close the 7-year EU research funding 2014-2020, Horizon2020. As a winner of the H2020 SME Instrument program, @genomebiologics appreciates all of the supports and benefits the EU have provided us during the project. More details nature.com/articles/d4158…

🎉🌲❄️⛄️🎁🎊 Genome Biologics wishes you and your family a Merry Christmas & a Safe, Healthy, and Prosperous New Year!!! #family #happiness #healthy

📣 📣 📣 PRESS RELEASE @genomebiologics is excited to announce entering into a Research Collaboration and Exclusive License Option Agreement with @AstraZeneca. 👉 More information is available at: lnkd.in/dPCbm5w #collaborations #drugdiscovery #cardiovascular

⏰⏰⏰ @genomebiologics is thrilled to attend the inaugural “Blue Knight Symposium” on 8th – 10th December 2020, focused on critical areas of interest in infectious disease, public health, and company acceleration. Stay tuned, and let’s connect. lnkd.in/d9m-8mF

📣📣📣 Our CTO Prof. Dr. Jaya Krishnan will have a talk "De-risking Rare Cardiovascular Disease Drug Discovery and Development" on 11th November at 15:50 GMT | 16:50 CET at the virtual event “BioData World Congress 2020”. Find out more: lnkd.in/edMH9kA #drugdiscovery

⏰ TODAY IS THE DAY ⏰ Connect with us, and let’s discuss with our CEO Jonathan Ward on our LIVE event “Using Computational Platforms for Drug Discovery” on 29th October 2020 at 15.00 CET. linkedin.com/events/thedial… #ArtificialIntelligence #drugs #COVID

🚀 What if we could use #AI to identify new drugs looking at the whole genome instead of single pathways? @genomebiologics can do that and more with our disruptive technologies! We are proud to be one of the Top 10 companies in Europe: labiotech.eu/ai/ai-drug-dis…

🎉 Congratulations 🎉 Genome Biologics is so excited to be one of the Top 5 Artificial Intelligent Startups in the Pharma sector. The scalability offered by #AI allows testing novel and existing drugs for a large number of targets at once. startus-insights.com/innovators-gui…